Aoxing Pharmaceutical Company Inc  

(Public, NYSEMKT:AXN)   Watch this stock  
Find more results for NYSEAMEX:AXN
0.790
+0.050 (6.76%)
Feb 12 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.75 - 0.80
52 week 0.50 - 3.48
Open 0.76
Vol / Avg. 97,075.00/171,706.00
Mkt cap 57.86M
P/E 7.97
Div/yield     -
EPS 0.10
Shares 76.21M
Beta 3.52
Inst. own 3%
Feb 8, 2016
Q2 2016 Aoxing Pharmaceutical Company Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin 15.42% 22.83%
Operating margin 35.90% 34.13%
EBITD margin - 36.62%
Return on average assets 10.01% 12.77%
Return on average equity 39.15% 125.84%
Employees 339 -
CDP Score - -

Address

1098 Foster City Blvd Ste 106-810
FOSTER CITY, CA 94404-2302
United States - Map
+1-646-3671747 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company, which specializes in research, development, manufacturing and distribution of a range of narcotics and pain-management products and drug-relief medicine. The Company's subsidiary, Hebei Aoxing Pharmaceutical Co., Inc., is engaged in developing narcotics and pain management products. Its products are produced in various formulations, such as injection, tablets, capsules, oral solution and powders. Its product, Zhongtongam, is a capsule of herbal extraction manufactured for the indication of oral and dental pain. Its product, Bismuth Potassium Citrate, is an oral solution containing bismuth subcitrate potassium, for the treatment of chronic gastritis and stomachache due to excessive stomach acid. Its product, Tilidine hydrochloride, is an orally absorbed synthetic narcotic analgesic. The Company is conducting a Phase II clinical trial on Tilidine/Naloxone capsules.

Officers and directors

Zhenjiang Yue Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
James Chen Chief Financial Officer
Bio & Compensation  - Reuters
Guirong Zhou President - Research and Development
Age: 61
Bio & Compensation  - Reuters
Guoan Zhang Vice President - Finance, Controller
Age: 45
Bio & Compensation  - Reuters
Jun Min Director
Age: 55
Bio & Compensation  - Reuters
Hui Shao Director
Age: 46
Bio & Compensation  - Reuters
Yang Li Independent Director
Age: 35
Bio & Compensation  - Reuters
Guozhu Xu Independent Director
Age: 69
Bio & Compensation  - Reuters